Based on the theory that inhibition of PARP results in the overexpression of PD‐L1 via GSK3β inactivation,41 University of Kentucky have developed 3 small‐molecule hybrid inhibitors of PARP and PD‐L1,and these results suggest that the properties of conjugates on tumor cells were enhanced compared with single drug.42 This evidence concerns the gene GSK3B and neoplasm.